Aiming to explore the role of EZH2 in multiple sclerosis, we first determined mRNA expression levels in PBMC from untreated patients and healthy individuals and observed that EZH2, together with molecules reported to be associated with cytosolic EZH2 such as TLN1 and VAV1 [3], were all downregulated in multiple sclerosis patients regardless of whether they were having relapse-onset or progressive clinical forms, or whether they were in clinical remission or in acute relapse. Here, VAV1 is linked to multiple sclerosis.